NEW YORK (360Dx) — French diagnostic and theranostics firm Theradiag on Wednesday reported a 9 percent decline in revenues for the first half of 2018 amid lower sales from its theranostics operations.

In its interim results for the six-month period ended June 30, Theradiag said its revenues fell to €4.6 million ($5.4 million) from €5.0 million in the same period of 2017. The company attributed the drop to non-recurring theranostics revenue from pharmaceutical partners in H1 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.